ENTL Entelos Regs

RNS Number:2415K
Entelos Inc.
19 December 2007


For immediate release                                           19 December 2007

                                  Entelos, Inc.


    Entelos Signs agreement with Johnson &Johnson Pharmaceutical Research and
                Development, LLC to Study Therapies for Diabetes
                                        
Foster City, CA, December 19, 2007 - Entelos, Inc. (LSE: ENTL), a leading life
sciences company building predictive computer models of human physiology and
"virtual patients" for drug discovery and development, announced today that it
has entered into an agreement with Johnson & Johnson Pharmaceutical Research &
Development, L.L.C. ("J&JPRD"), under which Entelos will use its "virtual
patients" approach as a platform to discover and evaluate potential new
therapies for treating type-2 diabetes. Financial terms were not disclosed.

"Finding the optimal therapies and treatment regimens for specific patient types
is a key strength of our in silico disease platforms," stated James Karis,
president and CEO of Entelos. "The deal reinforces Entelos' stated strategy to
enable proprietary drug development, particularly in chronic disease areas where
multiple drugs, treatment choices, and large differences between patients make
it difficult for health-care providers to select the best treatments. Type 2
diabetes is a classic example, where several standard therapies are available to
treat most patients in the earliest phases of their disease, but where diet,
exercise, multiple new drugs, or even surgery could be considered to gain better
control of high-blood sugar levels over the long term. We look forward to our
continued work in diabetes, an area of great medical need."

For further information please contact:
Entelos, Inc.                                             Tel: +1 650 572 5400

James Karis, President and CEO

Jill Fujisaki, VP, Investor
Relations

Buchanan Communications
Lisa Baderoon                                         Tel +44 (0) 20 7466 5000

Mary-Jane Johnson


Notes for Editors

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines are
discovered, developed, and utilized. The Company leverages its proprietary in
silico disease models, "virtual patients", and toxicology reference systems to
develop safer and more effective drugs and support pharmaceutical R&D and
commercialization. In addition to internal drug programs in rheumatoid arthritis
and women's health, Entelos provides customized technology and research services
to global pharmaceutical and health-care companies in cardiovascular diseases,
asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, and
skin sensitization. The company is also developing a model in oncology and is
collaborating with the FDA to build a model of drug-induced liver injury.
Entelos also offers cost-effective drug development capabilities through its
strategic alliance with India-based Jubilant Biosys.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
AGRFFUSMUSWSEDE

Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jun 2024 to Jul 2024

Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jul 2023 to Jul 2024